MFRP inhibitors, short for Membrane-Type Frizzled-Related Protein inhibitors, represent a class of chemical compounds that exert their effects on a specific cellular pathway involved in signal transduction and regulation. These inhibitors target the Membrane-Type Frizzled-Related Protein, or MFRP, which plays a crucial role in modulating cellular responses to extracellular signals, particularly those mediated by the Frizzled family of receptors. Frizzled receptors are integral components of the Wnt signaling pathway, a highly conserved and complex network that governs various biological processes, including embryonic development, tissue homeostasis, and cell proliferation. MFRP inhibitors, by interfering with the function of MFRP, can impact the Wnt signaling cascade and consequently influence a wide array of cellular activities.
The mechanism of action of MFRP inhibitors primarily involves the disruption of MFRP's interaction with Frizzled receptors, hindering the formation of functional signaling complexes. This disruption can occur at multiple points within the pathway, such as inhibiting the binding of MFRP to Frizzled receptors or blocking downstream signaling events. By interfering with this signaling pathway, MFRP inhibitors have to influence cell fate determination, tissue regeneration, and even tumorigenesis in various organisms. The development and study of MFRP inhibitors are of particular interest in the field of molecular biology and pharmacology, as they provide valuable insights into the intricate mechanisms governing cellular behavior and may hold promise for future applications in the realm of targeted interventions in a variety of contexts.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib inhibits tyrosine kinase activity, specifically targeting the BCR-ABL fusion protein, which is associated with chronic myeloid leukemia (CML). | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, inhibiting their activation. It's used for estrogen receptor-positive breast cancer by blocking estrogen's proliferative effects. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases involved in tumor growth and angiogenesis, including Raf kinases and VEGFR-2. It disrupts cancer cell signaling pathways, hindering tumor progression. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits mTOR (mammalian target of rapamycin) signaling, disrupting cell growth and proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks EGFR activation, suppressing tumor cell division, and is used in lung cancer therapy. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib targets the mutated BRAF kinase in melanoma. It inhibits the MAPK pathway, reducing cell proliferation and promoting apoptosis in BRAF-mutated melanoma cells. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, blocking the breakdown of ubiquitinated proteins and causing cell cycle arrest and apoptosis. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor studied in the research of B-cell malignancies. It disrupts B-cell receptor signaling and inhibits cancer cell survival. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK1/2 inhibitor that blocks the MAPK signaling pathway in cancer cells. It's used in melanoma and non-small cell lung cancer therapy. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits multiple kinases, including BCR-ABL and Src family kinases. | ||||||